2024 annual financial data
Karyopharm Therapeutics 2024 Operating margin
Direct answer
Operating margin was -82.24%.
Operating income was -119,443,000 USD and net income was -76,422,000 USD.
Operating cash flow was -127,486,000 USD.
Get free Karyopharm Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 145,237,000 USD
- Operating income
- -119,443,000 USD
- Net income
- -76,422,000 USD
- Operating cash flow
- -127,486,000 USD